Todd Zavodnick Founder of Excellergy Backed bySamsara BioCapitalSrinivas Akkaraju LinkedIn SourcesExcellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic Control — 2025-10 Browse all founders · Browse investors
